Topic summary

AOD-9604 and the fragment hypothesis, revisited — does this still hold?

Compounds › Other compounds research use only needs a source mislabelling Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 12, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.laurentTL28 Nov 2025#1

The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it.

What changes if the standard account of AOD-9604 is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.

Working through the consequences rather than the evidence, since others here are better placed on the evidence.

50 likes 9mo

k.kuuselaTL218 Dec 2025#2

The opening post is the version of this I will quote in future. One addition.

One caution on AOD-9604: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.

13 likes 7mo

IsaksenTL3Regular7 Mar 2026#5

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

Not a conclusion. A place to stand while looking for one.

20 likes 5mo

isotonic_driftTL1Member Solution31 May 2026#9

Filing a mild objection to the consensus on AOD-9604. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.

14 likes 2mo

i.amankwahTL227 Jul 2026#12

Posting my AOD-9604 numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.

11 likes 19h

Read the full topic (12 posts)

This topic was referenced in

Revisiting: Melanocortin agonists: mechanism and the documented adverse profileCompounds › Other compounds · 141 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+35	39	688	5mo
Naming conventions for research peptides and the confusion they cause — one year on Compounds › Other compounds research use only mislabelling needs a source Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. Asking about Naming conventions for research peptides…	+1	5	181	2y
Why catalogue breadth is not evidence of anything — what changed since Compounds › Other compounds custom synthesis mislabelling needs a source research use only Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since What changes if the standard account of catalogue breadth is wrong? I ask…	+62	66	26k	10mo
Reading a supplier's product description as a marketing document Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…	+86	97	62k	8mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds custom synthesis mislabelling research use only Solved Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Melanocortin agonists, from the point of…	+119	141	22k	20mo

Related topics — sharing the tags research use only, needs a source, mislabelling

Topic	Participants	Replies	Views	Activity
Insulin combinations and hypoglycaemia risk Practice › Interactions metformin needs a source hypoglycaemia insulin Closed On the subject in the title: Insulin combinations and hypoglycaemia risk Working notes rather than a conclusion. I was wrong about insulin combinations and hypoglycaemia risk in a thread last spring and I…	+18	22	7.8k	13mo
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. A follow-up question about Oral versus injected administration claims…	+23	27	7.7k	15mo
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…	+100	110	37k	5mo
[2026 update] Conference abstracts as evidence: the weakest common citation Evidence › Preprints needs a source effect size preprint risk of bias Closed Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Reading an unrefereed manuscript properly, and asking whether I am doing it…		2	48k	7mo
Citing a preprint in a maintained document: our rule and its reasoning Evidence › Preprints risk of bias effect size needs a source preprint Pinned On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. A preprint question rather than a question about the finding in it.…		2	467	4mo